Papillomavirus in Medical Technology

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date

... the two most common cervical cancer-causing human papillomavirus types for up to 6.4 years. This is the ... women were evaluated for the presence of human papillomavirus DNA by PCR using cervical samples and annual ... progression Approximately 100 types of human papillomavirus have been identified to date and, of these, ...

GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years

... the four most common cancer- causing human papillomavirus types for nearly six and a half years, the ... progression Approximately 100 types of human papillomavirus have been identified to date and, of these, ... L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from aluminium ...

Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention

... September in Chicago, Illinois. The paper, entitled " The Impact of Human papillomavirus Vaccination on Cervical Cancer Prevention Efforts, " is featured in the ... across the country. In addition to " The Impact of Human papillomavirus Vaccination on Cervical Cancer Prevention Efforts, " manuscript, ...

Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap

... Standard: QIA) digene HPV Test, which detects high-risk types of human papillomavirus that cause cervical cancer. "The implications of the findings of this ... is regarded as the "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than ...

Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders

... of prevention and detection, including HPV testing and vaccination." Human papillomavirus (HPV) is the primary cause of cervical cancer, and QIAGEN has developed ... tests available worldwide, including the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than ...

Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap

... International Journal of Cancer show that women screened only with a human papillomavirus (HPV) DNA test are half as likely to develop moderate to severe cervical ... tests available worldwide, including the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than ...

Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

... New HspE7 is an investigational therapeutic vaccine targeting human papillomavirus (HPV)-related diseases. (Logo: ... the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. ...

Divine Corporation's Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute

... research team, Divine has now been shown to be an extremely potent human papillomavirus inhibitor in their laboratory studies. While clinical tests have not yet ... JN, Muller M, Lowy DR, et al. (2006) Carrageenan Is a Potent Inhibitor of papillomavirus Infection. PLoS Pathog 2(7): e69 doi:10.1371/journal.ppat.0020069 About ...

Initiation of Coverage Informational Review Issued by Scimitar Equity Research

... and Vaccine Candidate for the Treatment of Diseases Caused by the Human papillomavirus (HPV)." The analyst research is available on Scimitar's website: ... vaccine candidate for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. ...

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

... by the University of Michigan have shown that as many as 15% of women in the study group determined to be negative for the presence of human papillomavirus (HPV) in the cervix, via the most commonly used test for HPV DNA, may actually be infected with the virus at clinically relevant viral loads. PCR-MS ...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

... 18,644 women, confirmed GlaxoSmithKline's Cervarix (R) is highly effective at protecting against the two most common cervical cancer-causing human papillomavirus (HPV) types, 16 and 18. The study also showed that the vaccine provides cross-protection against HPV types 31, 33 and 45, the three most common ...

SeqWright's Clinical Trial Support Contributes to the Approval of Two HPV Diagnostic Systems

... of contract genomic services, announced today its involvement in Hologic's (formerly Third Wave Technologies) successful clinical trials of two Human papillomavirus (HPV) in vitro diagnostic tests. SeqWright provided FDA submission quality DNA sequencing of multiple HPV strains and bioinformatics support to ...

Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks

... among men is cancer of the mouth related to tobacco use, and the No. 1 cancer among women is cancer of the cervix, which could be caused by human papillomavirus (HPV), poor perinatal care and lack of screening and early detection. In the immigrant population, by contrast, the top cancer is prostate cancer for ...

Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

... lead product candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 incorporates the proprietary adjuvant, Poly-ICLC, a toll-like ...

Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

... lead candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 incorporates the proprietary adjuvant, Poly-ICLC, a toll-like ...

Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

... lead candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 incorporates the proprietary adjuvant, Poly-ICLC, a toll-like ...

Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial

... candidate, HspE7 + Poly-ICLC, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 + Poly-ICLC contains the novel CoVal(TM) fusion protein, HspE7, that ...

Chimerix Initiates a Multi-dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection

... Chimerix President and CEO. "In addition to smallpox, we believe that CMX001 has great potential in treating other serious infections such as human papillomavirus and cytomegalovirus." CMX001 is being developed for the treatment of smallpox infection and other double stranded DNA virus infections that cause ...

The Oral Cancer Foundation Urges HPV Vaccination for Males

... cancer in the New England Journal of Medicine, the Oral Cancer Foundation is urging researchers to expedite investigations on the safety of human papillomavirus (HPV) vaccinations for males, and the FDA to fast track the approval once scientific due diligence has been accomplished. "The study affirms what ...

The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy

... National Cervical Cancer Coalition unites women in joining the fight for education and early detection and prevention of the Human papillomavirus (HPV) and cervical cancer WASHINGTON, Sept. 21 /PRNewswire-USNewswire/ -- More than 80 women and men gathered at the Hyatt ...

Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia

... an investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, in women with the highest ... for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually ... with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the ...

Gardasil Demonstrates Up to 100% Efficacy

... robust clinical data for any Human papillomavirus vaccine LYON, France, 10th May2007 – New ... the vast majority of genital Human papillomavirus diseases. It is estimated that among Human papillomavirus diseases in Europe, they cause 75% of cervical ...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

... cancer vaccine, Gardasil (Quadrivalent Human papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine). In ... Human papillomavirus (Types 6, 11, 16, 18) ... PHARMACOLOGY Disease Burden Human papillomavirus (HPV) causes squamous cell cervical cancer (and ...

Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18

... cancer vaccine, GARDASIL (Quadrivalent Human papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine) was ... Human papillomavirus (Types 6, 11, 16, 18) ... PHARMACOLOGY Disease Burden Human papillomavirus (HPV) causes squamous cell cervical cancer (and ...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

... of the women enrolled already had a human papillomavirus infection or abnormal cytology (abnormal Pap ... cancer and precancerous lesions caused by human papillomavirus types 16 and 18 for use in females ages 10 to 45 ... Bosch, X., et al. Efficacy of a human papillomavirus (HPV)-16/18 L1 virus-like particle (VLP) AS04 ...

Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years

... efficacy in preventing precancerous lesions due to cancer-causing human papillomavirus types 16 and 18 for up to 5.5 years in an extended follow-up trial, ... cervical cancer and its progression Approximately 100 types of human papillomavirus have been identified to date and, of these, approximately 15 virus types ...

Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age

... and social burden on women everywhere. At any given time, only 2.3 percent of women ages 14-59 are currently infected with cancer-causing human papillomavirus types 16 or 18. Only 0.1 percent is currently infected with both types. Therefore, the vast majority of these women (up to 99.9 percent) may benefit ...

Vaccine Can Prevent Cervical Cancer and Precancerous Lesions

... June 28, 2007--A cervical cancer vaccine has shown 90% efficacy for prevention of cervical cancer and precancerous lesions associated with the human papillomavirus (HPV) types targeted by the vaccine, conclude authors of an Article published early Online and in the upcoming issue of The Lancet. HPV types 16 and ...